Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 14/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14052237 | 0.84 | BRS3 (0.34) | BRS3 | |
| SCHEMBL502567 | 0.82 | BRS3 (0.73) | BRS3 | |
| SCHEMBL6982673 | 0.82 | BRS3 (0.67) | BRS3 | |
| SCHEMBL502974 | 0.71 | BRS3 (0.56) | BRS3 | |
| SCHEMBL6983651 | 0.69 | BRS3 (0.69) | BRS3 | |
| SCHEMBL6005772 | 0.68 | AGTR1 (0.63) | BRS3MMEAGTR1 | |
| SCHEMBL6004555 | 0.67 | AGTR1 (0.50) | BRS3MMEAGTR1 | |
| SCHEMBL6989344 | 0.67 | BRS3 (0.52) | BRS3 | |
| SCHEMBL9553128 | 0.66 | BRS3 (0.51) | BRS3LTB4R2MMEAGTR1 | |
| SCHEMBL9553290 | 0.66 | BRS3 (0.50) | BRS3LTB4R2MMEAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318767-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | SCHERING CORPORATION | 2012-04-12 | — | — | US | disclosed |
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | SCHERING CORPORATION | 2012-04-12 | — | — | US | disclosed |
| US-8106070-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | ALBANY MOLECULAR RESEARCH, INC. | 2010-01-07 | — | — | US | disclosed |
| WO-2008051404-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | BRS3, GPR119, GIPR | BRS3 1/4885LTB4R2 1830/4885MME 1139/4885 |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | BRS3 1/4885LTB4R2 1830/4885MME 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.